Originally called TransTech Pharma, in May 2015 the firm was renamed vTv Therapeutics LLC. A drug discovery company. vTv continues to develop a proprietary and efficient drug discovery engine called TTP - Translational Technology structured to utilize and translate genomic and proteomic data into safe and effective small molecule therapeutics in high throughput fashion, bypassing most of the classical requirements and bottlenecks in drug discovery. Utilized against a wide range of proprietary biological targets including protein-protein interaction and enzyme inhibitors and delivered small-molecule based preclinical drug candidates for the treatment of diabetes, cancer, inflammation, Alzheimer's disease and thrombosis, the system is lexible and scalable. With primary focus on Alzheimer's disease and Type 2 diabetes, the firm also engages in the discovery of preclinical and clinical drug candidates against multiple molecular target classes, such as kinases, GPCRs, phosphatases, proteases, and protein-protein interactions
